J&J MedTech Presents TECNIS PureSee Clinical Data

Johnson & Johnson MedTech presented new clinical data for the TECNIS PureSee IOL at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) meeting. The study highlights the lens's ability to provide a continuous range of vision while maintaining contrast sensitivity levels comparable to monofocal lenses. These findings suggest a significant advancement for patients seeking correction for presbyopia during cataract surgery. The data focuses on visual acuity at various distances and the incidence of visual artifacts like halos and glare.

Visual Acuity and Contrast Sensitivity

The clinical results demonstrate that the TECNIS PureSee IOL achieves high marks in distance and intermediate vision. Patients reported a smooth transition between different focal points, which is a common challenge with traditional intraocular lenses. The study measured contrast sensitivity under both photopic and mesopic lighting conditions to ensure performance in dim environments.

Researchers found that the lens design maintains a profile similar to a monofocal lens regarding light distribution. This design choice helps prevent the "waxy vision" sometimes associated with older multifocal technologies. The data indicates that 95% of patients achieved 20/20 distance vision within three months of the procedure.

The extended range of vision provided by this technology allows for better performance during daily tasks such as reading digital screens or driving at night. By minimizing the loss of light energy, the lens ensures that images remain sharp and clear. This performance consistency is a primary factor in the high satisfaction rates reported by clinical trial participants.

Clinical investigators also noted that the refractive predictability of the lens remained stable across various eye types. This reliability allows surgeons to plan procedures with greater confidence in the final visual outcome. The technology utilizes a unique refractive surface that manages light dispersion without the use of traditional diffractive rings.

"The data presented at ASCRS 2026 confirms that the TECNIS PureSee IOL provides patients with a high quality of vision across all lighting conditions while virtually eliminating the visual disturbances often associated with multifocal lenses."

— Peter Menziuso, Group Chairman, Vision at Johnson & Johnson

Minimizing Post-Operative Visual Artifacts

One of the most significant findings in the 2026 data involves the reduction of dysphotopsia. Patients using the TECNIS PureSee IOL reported a low incidence of halos, glare, and starbursts, which are frequent complaints after cataract surgery. This improvement is attributed to the purely refractive design of the lens surface.

By removing the diffractive steps found in other extended depth of focus lenses, Johnson & Johnson has addressed a major barrier to patient adoption. The absence of these rings reduces the scattering of light that typically causes nighttime visual issues. This makes the lens a viable option for patients who prioritize night driving or work in low-light settings.

The study also tracked patient-reported outcomes regarding spectacle independence. A majority of participants indicated they no longer required glasses for intermediate tasks like computer work or grocery shopping. While some patients still utilized reading glasses for very fine print, the overall reliance on corrective eyewear decreased significantly.

Surgeons at the ASCRS meeting discussed how these results might change the standard of care for refractive cataract surgery. The ability to offer a lens that behaves like a monofocal but provides the range of a multifocal is a notable shift in the market. This balance of performance and comfort remains a key objective for the ophthalmology sector.

The presentation of this data marks a milestone for the company’s vision care segment as it seeks to expand its footprint in the global intraocular lens market. As more surgeons integrate these findings into their clinical practice, the focus remains on optimizing patient satisfaction through objective visual metrics. Future studies will likely look at long-term stability and performance in a broader demographic of patients. This research underscores a commitment to advancing surgical outcomes through rigorous clinical validation.